These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35726771)

  • 1. Ferric pyrophosphate citrate for parenteral administration of maintenance iron: structure, mechanism of action, clinical efficacy and safety.
    Fishbane S; Ganz T; Pratt RD
    Curr Med Res Opin; 2022 Aug; 38(8):1417-1429. PubMed ID: 35726771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis.
    Pratt RD; Grimberg S; Zaritsky JJ; Warady BA
    Pediatr Nephrol; 2018 Nov; 33(11):2151-2159. PubMed ID: 30003313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients.
    Fishbane SN; Singh AK; Cournoyer SH; Jindal KK; Fanti P; Guss CD; Lin VH; Pratt RD; Gupta A
    Nephrol Dial Transplant; 2015 Dec; 30(12):2019-26. PubMed ID: 26175145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis.
    Shah HH; Hazzan AD; Fishbane S
    Semin Nephrol; 2016 Mar; 36(2):124-9. PubMed ID: 27236134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis.
    Fishbane S; Shah HH
    Hemodial Int; 2017 Jun; 21 Suppl 1():S104-S109. PubMed ID: 28371161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Ferric Pyrophosphate Citrate (Triferic) Use in Hemodialysis Patients.
    Albright T; Al-Makki A; Kalakeche R; Shepler B
    Clin Ther; 2016 Oct; 38(10):2318-2323. PubMed ID: 27692637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate.
    Marbury T; van Heuveln F; van der Horst E; Pratt RD
    J Clin Pharmacol; 2022 May; 62(5):681-688. PubMed ID: 34743348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease.
    Gan L; Xie P; Tan Y; Wei G; Yuan X; Lu Z; Pratt R; Zhou Y; Hui AM; Li K; Fang Y; Zuo L
    Drugs R D; 2022 Jun; 22(2):119-129. PubMed ID: 35380419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients.
    Gupta A; Lin V; Guss C; Pratt R; Ikizler TA; Besarab A
    Kidney Int; 2015 Nov; 88(5):1187-94. PubMed ID: 26154926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers.
    Pratt RD; Swinkels DW; Ikizler TA; Gupta A
    J Clin Pharmacol; 2017 Mar; 57(3):312-320. PubMed ID: 27557937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis.
    Gupta A; Amin NB; Besarab A; Vogel SE; Divine GW; Yee J; Anandan JV
    Kidney Int; 1999 May; 55(5):1891-8. PubMed ID: 10231452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis.
    Zhang L; Gan L; Li K; Xie P; Tan Y; Wei G; Yuan X; Pratt R; Zhou Y; Hui AM; Fang Y; Zuo L; Zheng Q
    Eur J Clin Pharmacol; 2022 Sep; 78(9):1421-1434. PubMed ID: 35711066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triferic for iron replacement.
    Med Lett Drugs Ther; 2017 Mar; 59(1517):55-56. PubMed ID: 28323812
    [No Abstract]   [Full Text] [Related]  

  • 14. New Options for Iron Supplementation in Maintenance Hemodialysis Patients.
    Vaziri ND; Kalantar-Zadeh K; Wish JB
    Am J Kidney Dis; 2016 Mar; 67(3):367-75. PubMed ID: 26616335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supplemental iron via dialysate: a novel mode of delivery for hemodialysis patients.
    Macdougall IC
    Kidney Int; 2015 Nov; 88(5):946-9. PubMed ID: 26579682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron Therapy in Chronic Kidney Disease: Days of Future Past.
    Lee KH; Ho Y; Tarng DC
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Aniort J; Greze C; Kosmadakis G
    Nephrol Ther; 2022 Dec; 18(6S1):6S25-6S32. PubMed ID: 36585122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.
    Nand N; Giri K; Jain D
    J Assoc Physicians India; 2019 Apr; 67(4):53-56. PubMed ID: 31311220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review.
    Bazeley JW; Wish JB
    Am J Kidney Dis; 2022 Jun; 79(6):868-876. PubMed ID: 34758368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.